Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMUNITY: Platform Trial for COVID-19 Treatments
NCT04590586Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies, Cyclic Peptides, Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of apremilast, lanadelumab, zilucoplan in coronavirus disease 2019 (COVID-19), sponsored by Amgen. Started Nov 2020; status: completed.
02
Drugs
apremilastlanadelumabzilucoplan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04590586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590586.